# Efficacy and Safety of Metformin Versus Empagliflozin on Chronic Kidney Disease Progression

Study · id `cardio:ct-nct05373680` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05373680](<https://clinicaltrials.gov/study/NCT05373680>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05373680

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 118 participants.

## Technical summary

Registry record NCT05373680. Randomized; no masking; primary purpose treatment. Start 2022-01-01 (actual); primary completion 2024-04-01 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 118 participants (enrolled count; ClinicalTrials.gov record NCT05373680, source copy `cardio:ctgov-nct05373680-2025-08-14`, retrieved 2026-10-26)
- Started: 2022-01-01 (actual) (ClinicalTrials.gov record NCT05373680, source copy `cardio:ctgov-nct05373680-2025-08-14`, retrieved 2026-10-26)
- Primary completion: 2024-04-01 (actual) (ClinicalTrials.gov record NCT05373680, source copy `cardio:ctgov-nct05373680-2025-08-14`, retrieved 2026-10-26)
- Completion: 2024-04-01 (actual) (ClinicalTrials.gov record NCT05373680, source copy `cardio:ctgov-nct05373680-2025-08-14`, retrieved 2026-10-26)
- Countries: Egypt (ClinicalTrials.gov record NCT05373680, source copy `cardio:ctgov-nct05373680-2025-08-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05373680-2025-08-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Metformin Versus Empagliflozin on Chronic Kidney Disease Progression
- Condition: Renal Insufficiency, Chronic
- Intervention (Drug): Metformin
- Intervention (Drug): Empagliflozin
- Intervention (Other): Control
- Lead sponsor: Tanta University
- Lead sponsor class: OTHER
- Collaborator: Mansoura University
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry intervention name matches this record: Empagliflozin (`cardio:empagliflozin`)
- Registry lists this organization as the lead sponsor: Tanta University (`cardio:org-tanta-university`)
- Registry lists this organization as a collaborator: Mansoura University (`cardio:org-mansoura-university`)

## Provenance

Content hash: 4e9ad1a9e227c4c1997b40c3bbec42625cf035eecf72370f802fa3bd8107f1a1
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
